Navigation Links
Parker Waichman LLP Represents Pennsylvania Man in Lawsuit Alleging Actos Caused his Bladder Cancer
Date:6/7/2013

New York, New York (PRWEB) June 07, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the victims of defective drugs, has filed a lawsuit on behalf of a Pennsylvania man who allegedly developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23rd in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1170) as part of the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff started taking Actos in November 2003 to treat his Type 2 diabetes. By August 2006, he was diagnosed with bladder cancer. The suit alleges that Actos caused the bladder cancer due to its defective nature. Furthermore, the suit alleges that the Defendants knew about the risk of bladder cancer but failed to disclose this information to consumers in order to protect financial interests. The Plaintiff is alleging that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk*. Additional research supports the link between Actos and bladder cancer. Last May, a study in the British Medical Journal** found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal*** found that patients taking the medication were
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. Parker Waichman LLC Applauds Seniors for their Role in Helping to Recover $14.9 billion in Medicare Fraud over the Past Four Years
2. Parker Waichman LLP’s Jordan Chaikin Is Appointed to the Executive Committee of the Plaintiff’s Leadership Team in Emerson Electric Co. Wet/Dry Vac Litigation
3. Woman with Bilateral DePuy Pinnacle Hip Implant Alleges Metal Hips are Flawed in Lawsuit Filed by Parker Waichman LLP
4. Atlantic City Hotel’s Negligence Caused Conditions that Led to Serious Injuries, Alleges Lawsuit Filed by Parker Waichman LLP
5. Parker Waichman LLP Files Appeal over the Pennsylvania Department of Environmental Protection’s Ruling that Natural Gas Wells Did not Harm Couple's Drinking Water Supply
6. Parker Waichman LLP Designated as Co-Lead Counsel in the Consolidation of Hurricane Sandy-related Litigation Against the Long Island Power Authority and/or National Grid
7. Medtronic Infuse Lawsuit News: Parker Waichman LLP Alerts the Public to the June Release of Yale’s Infuse Bone Graft Study
8. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
9. Mirena IUD Lawsuit Update: Supreme Court of New Jersey Centralizes Litigation; Parker Waichman LLP Underscores the Advantages of this Decision
10. DePuy Pinnacle Hip Implant Caused Elevated Ion Levels, Revision Surgery, Alleges Lawsuit Filed by Parker Waichman LLP
11. DePuy ASR Lawsuit Update: Parker Waichman LLP Commends Judge’s Refusal of Appeal for New Trial; DePuy Still Must Pay $8.3 Million Verdict
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at the ... Cancer Institute have received an $8 million grant from ... of photodynamic light therapy (PDT) in patients with malignant ... most often manifests itself in the lining of the ... asbestos. The grant will fund a clinical trial and ...
(Date:7/9/2014)... metabolism of stromal support cells and immune cells ... types in the development of diseases could open ... That was the conclusion of a review article by ... journal Nature . , Prof. Peter Carmeliet: "Consider ... metabolism of cancer cells has been examined in minute ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... Cup highlights, Brian Williams refreshing old school rap classics, ... railings. A University of Colorado Cancer Center study published ... YouTube also allows researchers, journals, and health advocates to ... cancer and prevention. , "No matter what field you,re ... communicate around the world," says Chante Karimkhani, MD candidate ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... , MINNEAPOLIS, June 9 Nonin Medical, Inc., ... history today by announcing the world,s first Bluetooth(R)-enabled ... now certified as compliant to the Continua(TM) Version ... Device Profile (HDP) and ISO/IEEE 11073 data protocol, ...
... from the Virginia Bioinformatics Institute (VBI) at Virginia Tech ... that allows them to profile in detail complex cellular ... to look at how the levels of proteins change ... hormones or cancer drugs like tamoxifen. VBI Assistant ...
... June 9 /PRNewswire-FirstCall/ -- Apria Healthcare Group ... ) (NYSE: PER ) today announced an ... to Apria Healthcare a range of healthcare information technology solutions, ... as well as consulting services. The term of the ...
... Resort Sponsors Scottish-Themed Charity Event , , OAK BROOK, Ill., June 9 ... night at the Oak Brook Hills Marriott Resort in Illinois. From 4:30 p.m. ... will be hosting the Oak Brook Hills Golf Classic to benefit the ... will feature: , , , ...
... you are getting full when eating a large meal? New ... may partially explain why severely obese individuals may not feel ... of food they consume during a meal. Researchers led ... and Diabetes Research Center focused on habituation, or the idea ...
... researchers determine that race has no bearing on life expectancy ... Older adults with mild cognitive impairment or Alzheimer,s disease have ... risk of death is no greater for whites or blacks, ... at Rush University Medical Center in Chicago, contradicts earlier information ...
Cached Medicine News:Health News:Nonin Medical, Inc. Announces the First Bluetooth(R) Continua(TM) Certified Product 2Health News:VBI researchers develop new method for breast cancer biomarker discovery 2Health News:Apria Healthcare Awards Technology Solutions Contract to Perot Systems 2Health News:Apria Healthcare Awards Technology Solutions Contract to Perot Systems 3Health News:Oak Brook Hills Golf Classic to Benefit the Children's Miracle Network 2Health News:Physiological response may explain why some severely obese patients overeat 2Health News:Alzheimer's and Even Mild Dementia Hasten Death 2
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage ... positive, statistically significant top-line results from its ANCHOR trial for ... met its primary and secondary efficacy endpoints for both the ... The purpose of the ANCHOR trial was to demonstrate that ...
... and SYDNEY, April 15, 2011 HeartWare International, ... a leading innovator of less invasive, miniaturized circulatory ... advanced heart failure, today announced the presentation of ... transplantation (BTT) study, ADVANCE, showing 180-day survival, using ...
Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5
West 2 periosteal elevators....
Semb periosteal elevators....
Williger periosteal elevators....
Lambotte periosteal elevators....
Medicine Products: